Urakami Shinji, Shiina Hiroaki, Sumura Masahiro, Honda Satoshi, Wake Koji, Hiraoka Takeo, Inoue Shogo, Ishikawa Noriyoshi, Igawa Mikio
Department of Urology, Shimane University School of Medicine, 89-1 Enya-cho, Izumo 693-8501, Japan.
Int Urol Nephrol. 2008;40(2):365-8. doi: 10.1007/s11255-007-9301-z.
Metastatic prostate cancer (PC) is incurable by androgen deprivation therapy alone, due to the presence of androgen-independent/supersensitive cells in hormone-naive PC. A 67-year-old man was diagnosed with PC (Gleason score, 5 + 4) with multiple bone metastases. He was treated by chemohormonal therapy with cisplatin and estramustine phosphate (EMP) followed by maximal androgen blockade, and showed a complete response. As of the time of writing, no clinical or prostate-specific antigen recurrence has been observed for over 15 years, despite cessation of the treatment. This is the first report to indicate a possible cure of metastatic PC by chemohormonal therapy combined with appropriate anti-tumor drugs targeted to both androgen-independent and -dependent clones before the hormone-refractory state.
由于在未经激素治疗的前列腺癌中存在雄激素非依赖/超敏细胞，仅靠雄激素剥夺疗法无法治愈转移性前列腺癌。一名67岁男性被诊断为前列腺癌（ Gleason评分，5 + 4）伴多发骨转移。他接受了顺铂和磷酸雌莫司汀（EMP）的化学激素疗法，随后进行了最大限度雄激素阻断治疗，并显示出完全缓解。截至撰写本文时，尽管停止了治疗，但15多年来未观察到临床或前列腺特异性抗原复发。这是第一份表明在激素难治状态之前，通过化学激素疗法联合针对雄激素非依赖和依赖克隆的适当抗肿瘤药物可能治愈转移性前列腺癌的报告。
